Results 201 to 210 of about 14,856,428 (286)

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

British Journal of Haematology, EarlyView.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi, Nandakumar Natarajan, Kathryn E. Dickerson, Richard A. Voit   +3 more
wiley   +1 more source

Performance of PRAME Immunohistochemistry in Distinguishing Classic Hodgkin Lymphoma from Anaplastic Large Cell Lymphoma and T-Cell Lymphoma. [PDF]

Cancers (Basel)
Duan X, Williams KN, Chen AL.
europepmc   +1 more source

Mosaic chromosomal alterations and relation to haematological cancer in two large Danish cohorts

British Journal of Haematology, EarlyView.
Summary Mosaic chromosomal alterations (mCAs) are large somatic gains, losses and copy‐neutral loss of heterozygosity identified in the peripheral blood, which represent a relatively unexplored spectrum of clonal haematopoiesis. We aimed to describe mCAs in two large Danish cohorts with extensive long‐term registry‐based follow‐up and examine ...
Cecilie Velsoe Maeng, Pei Meng, Mathias Heldbo, Olafur Davidsson, Morten Munk Johansen, Sigrún Thorsteinsdóttir, Jojo Biel‐Nielsen Dietz, Ragnar Pétur Kristjansson, Ole Birger Vesterager Pedersen, Erik Sørensen, Christian Erikstrup, Christina Mikkelsen, Nanna Brøns, Henrik Ullum, Bitten Aagaard, Mie Topholm Bruun, Estrid Høgdall, DBDS Research Consortium, CHB Research Consortium, Bo Porse, Simon Husby, Sisse R. Ostrowski, Henrik Hjalgrim, Kirsten Grønbæk   +23 more
wiley   +1 more source

T-cell lymphoma of the breast and ovary presenting as a second malignant neoplasm in a pediatric leukemia survivor: A case report and literature review. [PDF]

Rare Tumors
Alvarez-Palacios O, Ojeda-Campos L, Rodríguez A, Díaz-Juarez GE, Figueroa-Torres JM, Juárez-Velázquez R, Juárez-Figueroa U, Gallardo-Navarro JJ, Segundo-Galvez LF, Ocampo-Bárcenas A.   +9 more
europepmc   +1 more source

Prognostic impact of blood Epstein–Barr virus‐DNA in patients with peripheral T‐cell lymphoma, not otherwise specified

British Journal of Haematology, EarlyView.
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon, Hyungwoo Cho, In Hye Song, Sejin Kim, So Heun Lee, Kyoungmin Lee, Shin Kim, Chan‐Sik Park, Eun Jin Chae, Kyung Won Kim, Jin‐Sook Ryu, Sang‐Wook Lee, Jaewon Hyung, Heounjeong Go, Dok Hyun Yoon   +14 more
wiley   +1 more source

Safety and Effectiveness of Denileukin Diftitox-cxdl in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma: An All-Case Post-Marketing Study in Japan. [PDF]

Cancer Rep (Hoboken)
Jo T, Matsumoto K, Ishii M, Izutsu K.
europepmc   +1 more source

Comorbid conditions after allogeneic haematopoietic stem cell transplantation in young adults in Germany—A prospective, multicentre trial

British Journal of Haematology, EarlyView.
Summary Young adults (YA) are particularly affected by comorbid conditions following allogeneic haematopoietic stem cell transplantation (alloHSCT), as they have to live with them for many years. This is the first multicentre prospective study investigating sequelae after alloHSCT in YA in Germany. In total, 107 patients who survived relapse‐free until
Pauline Rocke, Lena Tandetzky, Daniel Wolff, Katharina Egger‐Heidrich, Daniela Heidenreich, Kerstin Schaefer‐Eckart, Eva Wagner‐Drouet, Jochen J. Frietsch, Andreas Hochhaus, Inken Hilgendorf   +9 more
wiley   +1 more source

Rare Presentation of Sequential Mucosa-Associated Lymphoid Tissue Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leukemia: A Case-Based Review. [PDF]

J Community Hosp Intern Med Perspect
Desai KJ, Patel AH, O'Dowd PT, Tworek JA, Misra PG, Ding L.   +5 more
europepmc   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T-Cell Lymphoma. [PDF]

Hematol Oncol
Saeed H, Varela MM, Sahakian E, Naqvi M, Mo Q, Zhang L, Makanji R, Zhang Y, Dong N, Isenalumhe L, Gaballa S, Chavez J, Shah B, Bello C, Sokol L, Pinilla-Ibarz J.   +15 more
europepmc   +1 more source